A hot topic in the type 2 diabetes world is whether we have in hand the tools to stop the decline in beta cell function that typifies this disease and, consequently, a therapy or therapies that successfully control blood glucose for many years – so-called treatment durability. Actually this is three topics. What are the specific mechanisms for the beta cell failure? Do any of our existing therapies, or those on the drawing board, reverse these mechanisms to slow or stop the beta cell failure?
Do you recognize this patient? I have seen him in my office, or a person just like him. The Center for Disease Control (CDC, HHS) estimates that 57 million people in the U.S. have pre-diabetes. (1) If you look, you can probably recognize a person like this in every primary care office in the U.S. Unfortunately we still don’t have an evidence-based answer for the best therapeutic course for treatment of pre-diabetes.
Doron Schneider, MD, a leading primary care physician and Jack Leahy, MD, a world-renowned beta cell researcher, discuss the new concepts, current research and therapies. (48:08)
A leading primary care physician and a world-renowned beta cell researcher discuss why it is important for primary care doctors to understand the role of beta cells in type 2 diabetes. (13:53)
Frequently asked questions for the primary care community, excerpted from a conversation between a leading primary care physician and a world-renowned beta cell researcher. (1:07)
Frequently asked questions for the primary care community, excerpted from a conversation between a leading primary care physician and a world-renowned beta cell researcher. (2:30)